UK Biotech Star Oxford Nanopore To Reject IPO For £1.6 Billion Private Round

by Jonathan Adams
UK Biotech

Oxford Nanopore, a gene-analysis start-up that is considered to be one of the UK’s most promising biotech companies, is reportedly edging towards ditching its IPO plans in favour of another big private investment round. The company, developing a new generation of DNA-reading and sequencing biotechnology, is one of a handful of UK biotech ‘unicorns’, having achieved a valuation of £1.5 billion during its last investment round that saw Californian biotech giant Amgen invest £50 million. A ‘unicorn’ is the term assigned to any start-up valued at $1 billion (£0.78 billion) or more.

Oxford Nanopore was spun-out from Oxford University as a private company in 2005 but is still loss making. Last year the start-up lost £53.1 million on revenues of £32.5 million. That was, however, an improvement on 2017 losses of £56.5 million. As well as the £50 million investment made by Amgen, Nanopore raised another £100 million in a March 2018 round from investors including Singapore’s GIC, China Construction Bank and Australia’s Hostplus. DNA sequencing is a quickly developing and potentially hugely lucrative industry. Advances in AI and biotech have seen leaps forward in making DNA sequencing and editing faster, easier and more affordable in recent years.

The biotechnology being developed by Nanopore is able to pull strands of DNA through tiny holes in protein molecules – known as ‘nanopores’. Doing so allows the DNA’s sequence to be read. The biotech ‘machines’ that achieve this feat have shown significant promise but there have also been criticisms levelled at the tech’s accuracy, which some scientists believe is unable to provide the same level of accuracy as competitors including gene-sequencing giant Illumina. However, this in no way means the biotechnology is not potentially hugely valuable. It is still being developed and is likely to be improved upon and is cheaper to use than that of Illumina. That means that even if the level of accuracy it affords is not suitable for every form of DNA analysis, it still has a significant potential market. The market that Oxford Nanopore is targeting is expected to be worth almost $12 billion globally within 5 years.


In spring this year, the company announced to investors that it was planning a stock market listing through an IPO. However, possibly influenced by the travails of several high profile, loss-making technology companies that have gone to IPO this year, it looks as though Oxford Nanopore has had a change of heart. The Sunday Times reports that it is instead conducting talks around a ‘secret’ new private fundraising round targeting a further £1.6 billion of investment.

That’s possibly bad news for Neil Woodfords recently shut down Woodford Equity Income Fund, which is a major investor in Nanopore. It needs to liquidate its holdings for as much money to be returned to investors as possible and an IPO would have represented an ideal opportunity for it to do so – potentially for a good return. However, all may not still be lost if a new investment round at a higher valuation takes place. That should help the fund find a buyer for its own stake. Other investors could be willing to take Woodford’s equity holdings at a price that is lower than the new investment round values the company, but still representing a profit on the original investment.

This article is for information purposes only.
Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.

Related News

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Know more